Skip to main content
Equibles

CORONA · CORONA Remedies Limited

Use CORONA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CORONA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,329.70 INR -12.50 (-0.53%) At close · Nov 13
Rebalance outlook locked
Market Cap
142.48B INR
Shares
61.16M
Volume · Nov 13 25.79K Avg daily vol (3M) 45.81K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close2,329.70 INR Open2,350.80 INR Day2,318.00–2,391.90 INR Available close range1,347.70–2,539.40 INR Avg vol 30d48K Last earningsNov 2, 2026 DataDec 2025–Nov 2026

The closing range uses available history since Dec 15, 2025; less than a full year is stored.

Latest documents

2026
Nov 2
Earnings call
Q2 revenue and EBITDA rise 22.2% and 22.3%

CORONA Remedies reported Q2 FY27 revenue of INR441 crores, up 22.2% YoY, while EBITDA rose 22.3% to INR96 crores and H1 PAT grew 22.2% to INR120 crores.

4 source passages
Good morning, everyone. On behalf of Ambit Capital, we welcome you to the 2Q and 1HFY27 earnings conference call of CORONA Remedies Limited. Speaking of performance, revenue for Q2 FY27 stood at INR441 crores versus INR361 crores in Q2 FY26, reflecting a healthy growth of 22.2% YoY revenue growth in Q2. EBITDA for the quarter stood at INR96 crores versus INR78.5 crores in Q2 FY26, a growth of 22.3% on a year-on-year basis. PAT for H1 FY27 stood at INR120 crores, a growth of 22.2% YoY, whereas PAT margin for H1 FY27 stood at 13.9%. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
· 3.61B INR 523.20M INR '26 Q2 · 3.42B INR 412.70M INR '26 Q3 · 3.53B INR 453.30M INR '26 Q4 · 4.22B INR 601.10M INR '27 Q1 LATEST ▲22.2% 4.41B INR 603.10M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its available closing range
Range low 1,347.70 INR Now 2,329.70 INR · 82% Range high 2,539.40 INR
vs 200-day avg +25% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:CORONA -4.6% +13.9% +38.3% +8.4% +68.2%

Exchange listing

Market
XNSE
Ticker
CORONA
ISIN
INE02ZQ01018
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.coronaremedies.com/
Investor relations
https://www.coronaremedies.com/investors

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-06-19 10.00 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-02 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-03 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-12 Transcript
    Earnings Call for the Quarter Ended March 31, 2026